Yan L - Search Results

1

Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.

Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Xia Z, et al. Among authors: yan l. BMC Cancer. 2023 Oct 14;23(1):980. doi: 10.1186/s12885-023-11489-8. BMC Cancer. 2023. PMID: 37838670 Free PMC article. Clinical Trial.

2

[Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review].

Yan LZ, Shang JJ, Shi XL, Qu S, Kang LQ, Xu N, Chang WR, Yu L, Wu DP, Fu CC. Yan LZ, et al. Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):650-655. doi: 10.3760/cma.j.issn.0253-2727.2019.08.005. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495131 Free PMC article. Review. Chinese.

3

[Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].

Yao WQ, Zhu MQ, Yan LZ, Jin S, Shang JJ, Yao Y, Yan S, Liu Y, Wu DP, Fu CC. Yao WQ, et al. Among authors: yan lz, yan s. Zhonghua Xue Ye Xue Za Zhi. 2019 Sep 14;40(9):720-725. doi: 10.3760/cma.j.issn.0253-2727.2019.09.002. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31648471 Free PMC article. Chinese.

4

Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C. Yan L, et al. Cancer Med. 2021 Jan;10(2):563-574. doi: 10.1002/cam4.3624. Epub 2020 Dec 23. Cancer Med. 2021. PMID: 33356013 Free PMC article.

5

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.

An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L. An G, et al. Among authors: yan l. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. doi: 10.1158/1078-0432.CCR-21-0539. Epub 2021 Jul 12. Clin Cancer Res. 2021. PMID: 34253577 Free PMC article. Clinical Trial.

6

[The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].

Liu Y, Xu Y, Xie Y, Chen GH, Liu W, Yao WQ, Yan S, Yan LZ, Wu DP, Fu CC. Liu Y, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1187-1194. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.026. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 34362501 Chinese.

7

[Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma].

Yao L, Chen Y, Zhai YY, Shi XL, Cen JN, Yan LZ, Fu CC, Chen SN. Yao L, et al. Among authors: yan lz. Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):683-686. doi: 10.3760/cma.j.issn.0253-2727.2021.08.013. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34547877 Free PMC article. Chinese. No abstract available.

8

Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.

Kong D, Li Y, Fu C, Hou M, Yan L, Shang J, Wang Z, Yin J, Yu Z, Wu D. Kong D, et al. Among authors: yan l. Leuk Lymphoma. 2022 Feb;63(2):491-494. doi: 10.1080/10428194.2021.1992766. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668450 No abstract available.

9

[Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].

Xu Y, Zhou J, Ma L, Jin S, Yan LZ, Shang JJ, Wu DP, Fu CC. Xu Y, et al. Among authors: yan lz. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Dec;29(6):1831-1836. doi: 10.19746/j.cnki.issn.1009-2137.2021.06.024. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 34893119 Chinese.

10

Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.

Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, Zhu M, Chang H, Gong F, Zhou J, Chen G, Pan J, Liu D, Zhu X, Tang F, Liu M, Liu W, Yao F, Yu L, Wu D, Fu C. Shi X, et al. Among authors: yan l, yan z. Am J Hematol. 2022 May;97(5):537-547. doi: 10.1002/ajh.26486. Epub 2022 Feb 9. Am J Hematol. 2022. PMID: 35114022 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,689 results

Search Page

Filters